| 16-May-13 08:30AM | Peregrine Pharmaceuticals' Immunotherapy Bavituximab to Be Highlighted in Three Clinical Data Presentations at 2013 ASCO Annual Meeting Marketwired |
| 08:30AM | Peregrine Pharmaceuticals' Immunotherapy Bavituximab to Be Highlighted in Three Clinical Data Presentations at 2013 ASCO Annual Meeting Marketwire |
| 08-May-13 05:55PM | Osiris Loss In-Line with Expectations Zacks |
| 10:14AM | PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online |
| 03-May-13 10:18PM | Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential at Seeking Alpha |
| 29-Apr-13 08:14PM | Is Peregrine Preparing to Soar Again? at Motley Fool |
| 06:22PM | 4 Healthcare Stock Stories To Kick Off the Trading Week at Wall St. Cheat Sheet |
| 08:30AM | Peregrine Announces Completion of Patient Enrollment in Breast Cancer Clinical Trial for Bavituximab Marketwired |
| 08:30AM | Peregrine Announces Completion of Patient Enrollment in Breast Cancer Clinical Trial for Bavituximab Marketwire |
| 23-Apr-13 08:43AM | Threshold: My Biotech Pick Of The Year at Seeking Alpha |
| 10-Apr-13 05:15PM | 4 Healthcare Stock Stories for Savvy Midweek Investment at Wall St. Cheat Sheet |
| 08:30AM | InPlay: Peregrine Pharma: Data presented at AACR annual meeting support targeted immune reactivation mechanism and potential of Peregrine's bavituximab in solid tumor therapy Briefing.com |
| 08:30AM | Data Presented at AACR Annual Meeting Support Targeted Immune Reactivation Mechanism and Potential of Peregrine's Bavituximab in Solid Tumor Therapy Marketwired |
| 08:30AM | Data Presented at AACR Annual Meeting Support Targeted Immune Reactivation Mechanism and Potential of Peregrine's Bavituximab in Solid Tumor Therapy Marketwire |
| 09-Apr-13 08:00AM | Faruqi & Faruqi, LLP is Investigating Peregrine Pharmaceuticals Inc. on Behalf of its Shareholders - PPHM PR Newswire |
| 04-Apr-13 01:53PM | 5 Stocks Under $10 Set to Soar at TheStreet |
| 01-Apr-13 04:00PM | InPlay: Peregrine Pharma announces three abstracts accepted for presentation at AACR 2013 Annual Meeting Briefing.com |
| 04:00PM | Peregrine Announces Three Abstracts Accepted for Presentation at AACR 2013 Annual Meeting Marketwired |
| 04:00PM | Peregrine Announces Three Abstracts Accepted for Presentation at AACR 2013 Annual Meeting Marketwire |
| 21-Mar-13 07:12PM | On The Fly: After Hours Movers theflyonthewall.com |
| 20-Mar-13 03:03PM | Follow The Crashing Biotechs: 4 Stocks Fresh From A Fall at Seeking Alpha +6.02% |
| 18-Mar-13 12:17PM | 3 Stocks That Blew the Market Away at Motley Fool |
| 09:19AM | On The Fly: Pre-market Movers theflyonthewall.com |
| 16-Mar-13 01:04PM | PEREGRINE PHARMACEUTICALS INC Financials EDGAR Online Financials |
| 07:00AM | A Fool Looks Back at Motley Fool |
| 13-Mar-13 06:48PM | New Star Analyst Rankings for Peregrine Pharmaceuticals Inc. StarMine -6.33% |
| 05:29PM | Peregrine Releases Earnings, But The Situation Remains The Same at Seeking Alpha |
| 04:48PM | Peregrine Reports Narrower Loss Zacks |
| 09:10AM | On The Fly: Pre-market Movers theflyonthewall.com |
| 09:00AM | Peregrine Pharmaceuticals, Synergetics Announce Earnings at Forbes |
| 12-Mar-13 07:40PM | Peregrine Pharmaceuticals Management Discusses Q3 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 07:18PM | On The Fly: After Hours Movers theflyonthewall.com |
| 06:48PM | Peregrine Pharmaceuticals Earnings: Heres Why Investors are Excited Now at Wall St. Cheat Sheet |
| 06:32PM | February's Biggest Biotech Loser Bounces Back at Motley Fool |
| 06:31PM | Peregrine Pharma reports smaller 3Q loss AP |
| 05:03PM | InPlay: Peregrine Pharma beats by $0.03, beats on revs Briefing.com |
| 04:50PM | After-Hours Buzz: BA, URBN & More at CNBC |
| 04:16PM | PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo EDGAR Online |
| 04:00PM | Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2013 Financial Results and Recent Developments Marketwire |
| 07:07AM | Q3 2013 Peregrine Pharmaceuticals Earnings Release - After Market Close CCBN |
| 11-Mar-13 10:51AM | 5 Reasons Not to Worry This Week at Motley Fool |
| 08:20AM | FDA's New "Breakthrough" Designation Allows New Drugs to Gain Approval After Just 1 Round of Testing Marketwire |
| 09-Mar-13 12:30PM | Peregrine Pharmaceuticals Earnings: An Early Look at Motley Fool |
| 08-Mar-13 11:38AM | Largest option buying in equities so far optionMONSTER +12.86% |
| 08:09AM | Why These 4 Biotechs Could Be Next In Line To See Their Share Prices Rise at Seeking Alpha |
| 03:15AM | George Zavoico: Biotech Stocks That Deserve A Closer Look at Seeking Alpha |
| 07-Mar-13 09:26AM | On The Fly: Pre-market Movers theflyonthewall.com |
| 06-Mar-13 09:26AM | On The Fly: Pre-market Movers theflyonthewall.com +5.34% |
| 05-Mar-13 07:29PM | 2 Biotech Superstars For 2013 at Seeking Alpha |
| 04:38PM | After-Hours Buzz: PAY, NTRI, PLL & More at CNBC |
| 04:00PM | Peregrine to Report Third Quarter Fiscal Year 2013 Financial Results After Market Close on March 12, 2013 Marketwire |
| 28-Feb-13 10:24PM | These 3 Stocks Fell Like a House of Cards at Motley Fool |
| 26-Feb-13 04:00PM | Peregrine Announces Participation at Upcoming Investor Conferences Marketwire -12.95% |
| 03:20PM | Avid Bioservices to Highlight Recent Successes in Reducing Manufacturing Costs and Novel Ways of Controlling Critical Process Parameters That Lead to Consistent Product Quality at IBC'S Biopharmaceutical Development and Production Conferenc Marketwire |
| 05:49AM | Peregrine Pharmaceuticals' Bavituximab: It's Time To Throw In The Towel at Seeking Alpha |
| 21-Feb-13 08:25PM | A Biotech Winner For 2013 at Seeking Alpha |
| 20-Feb-13 01:18PM | Update on Peregrine's Bavituximab Zacks -6.21% |
| 19-Feb-13 04:21PM | PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 11:41AM | Peregrine Investors: Once Bitten, Twice Shy at Motley Fool |
| 11:06AM | Largest option buying in equities so far optionMONSTER |
| 08:33AM | 2 of These 3 Stocks Look Like Damaged Goods at Motley Fool |
| 08:30AM | InPlay: Peregrine Pharma updates top-line data from Phase II clinical trial of Bavituximab; 60% improvement in median overall survival in patients treated with Bavituximab plus Docetaxel Briefing.com |
| 08:30AM | Peregrine Pharmaceuticals Updates Top-Line Data From Phase II Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer Marketwire |
| 14-Feb-13 03:28PM | Data on Peregrine's Bavituximab Zacks +8.28% |
| 01:48PM | Peregrine's Epic Failure (Maybe) at Motley Fool |
| 08:20AM | U.S. Food and Drug Administration Approved 30% More Drugs in 2012 Marketwire |
| 07:57AM | Today's Market News To Trade On: 5 Stocks Moving On News at Seeking Alpha |
| 13-Feb-13 04:36PM | 4 Heathcare Stock Stories Necessary for Investor Wellness at Wall St. Cheat Sheet -19.91% |
| 04:21PM | PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 01:31PM | Can Peregrine Match Celgene? No. at Motley Fool |
| 09:44AM | Peregrine Pharma Is Wasting Money On A Placebo Cancer Drug at TheStreet |
| 08:30AM | InPlay: Peregrine Pharma announces results from Phase II clinical trial of Bavituximab in Stage IV Pancreatic Cancer; top-line results demonstrate signs of anti-tumor activity in difficult to treat patient population; co evaluating next ste Briefing.com |
| 08:30AM | Peregrine Pharmaceuticals Announces Results From Phase II Clinical Trial of Bavituximab in Stage IV Pancreatic Cancer Marketwire |
| 12-Feb-13 04:08PM | Priority FDA Review for Celgene Drug Zacks |
| 11:34AM | Whats Moving These Biotech Stocks? at Motley Fool |
| 11-Feb-13 05:43PM | Gilead Closes YM Biosciences Buyout Zacks |
| 07-Feb-13 05:43PM | Protalix Exploring Options Zacks |
| 05:00PM | 50% Upside on this Biotechnology Stock at Motley Fool |
| 04:43PM | SGEN Starts SGN-CD19A Phase I Study Zacks |
| 04:38PM | Pipeline Setback for Idenix Zacks |
| 03:58PM | Medivation's Xtandi Impresses Zacks |
| 03:57PM | Speculative Biotech Stocks That Could Bounce at Seeking Alpha |
| 01:08PM | Vivus Unveils Qsymia Study Results Zacks |
| 05-Feb-13 09:04AM | Whoa! These 3 Stocks Rode the Dow Higher at Motley Fool |
| 08:58AM | Gilead Beats Estimates in 4Q Zacks |
| 04-Feb-13 05:18PM | Canada Approves Seattle Genetics' Adcetris Zacks |
| 03-Feb-13 04:17PM | 3 Biotechs Burning Through Cash at Motley Fool |
| 30-Jan-13 09:32AM | Buy, Sell, or Hold: Peregrine Pharmaceuticals at Motley Fool -7.00% |
| 24-Jan-13 08:20AM | Mergers and Acquisitions on the Rise in 2013 as Big Pharma Companies Hold Record Amounts of Cash on Hand Marketwire |
| 19-Jan-13 04:21PM | The Good, The Bad, and The Ugly with The Medicines Company at Motley Fool |
| 18-Jan-13 01:47PM | Will the Feuerstein-Ratain Rule Hold in 2013? at Motley Fool |
| 08:18AM | Biotech Stock Mailbag: Peregrine, Arena, Dendreon, NPS Pharma at TheStreet |
| 17-Jan-13 03:13PM | 2 Speculative Stocks Soaring in 2013 at Motley Fool |
| 16-Jan-13 04:08PM | Alnylam Prices Public Offering Zacks |
| 15-Jan-13 04:33PM | Alnylam to Raise $125 Million Zacks |
| 14-Jan-13 08:05AM | This Week in Biotech at Motley Fool |
| 08:00AM | Surviving BioTech: How the Game is Played Phase Funding, Drug Approvals and Resulting Revenue PR Newswire |
| 10-Jan-13 01:28PM | Geron's Update on Stem Cell Assets Zacks |
| 09-Jan-13 02:55PM | Down 10%: Peregrine Hits the Brakes at Motley Fool -11.59% |
| 09:18AM | Peregrine Recovers As Phase II Trial Is Salvaged at Seeking Alpha |
